Cited by 4,847

The DOI matches its Crossref record; 254 of the 254 references it cites were found in a registry or an index.

Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)

Wang, Jiang, Sánchez-Roselló, María, Aceña, José Luis, del Pozo, Carlos, Sorochinsky, Alexander E., Fustero, Santos, Soloshonok, Vadim A., Liu, Hong·2014·Chemical Reviews

DOI 10.1021/cr4002879

Open this paper in CoChat — free account

Abstract

ADVERTISEMENT RETURN TO ISSUEPREVReviewNEXTFluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)Jiang Wang†, María Sánchez-Roselló‡§, José Luis Aceña∥, Carlos del Pozo‡, Alexander E. Sorochinsky∥⊥#, Santos Fustero*‡§, Vadim A. Soloshonok*∥⊥, and Hong Liu*†View Author Information† Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China‡ Department of Organic Chemistry, Faculty of Pharmacy, University of Valencia, Av. Vicente Andrés Estellés, 46100 Burjassot, Valencia, Spain§ Laboratorio de Moléculas Orgánicas, Centro de Investigación Príncipe Felipe, C/ Eduardo Primo Yúfera 3, 46012 Valencia, Spain∥ Department of Organic Chemistry I, Faculty of Chemistry, University of the Basque Country UPV/EHU, Paseo Manuel Lardizábal 3, 20018 San Sebastian, Spain⊥ IKERBASQUE, Basque Foundation for Science, Alameda Urquijo, 36-5 Plaza Bizkaia, 48011 Bilbao, Spain# Institute of Bioorganic Chemistry and Petrochemistry, National Academy of Sciences of Ukraine, Murmanska Street 1, 02660 Kyiv-94, Ukraine*E-mail: [email protected]*E-mail: [email protected]*E-mail: [email protected]Cite this: Chem. Rev. 2014, 114, 4, 2432–2506Publication Date (Web):December 3, 2013Publication History Received27 May 2013Published online3 December 2013Published inissue 26 February 2014https://pubs.acs.org/doi/10.1021/cr4002879https://doi.org/10.1021/cr4002879review-articleACS PublicationsCopyright © 2013 American Chemical SocietyRequest reuse permissionsArticle Views48704Altmetric-Citations3850LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose SUBJECTS:Anions,Fluorine,Organic compounds,Pharmaceuticals,Reaction products Get e-Alerts

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1021/cr4002879

Cites

254 of 254 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Fluorine in medicinal chemistry
Purser, S., Moore, P. R., Swallow, S., & Gouverneur, V. (2008) · Chem. Soc. Rev. · doi:10.1039/b610213c · Cited by 7,570
Fluorine in Pharmaceuticals: Looking Beyond Intuition
Müller, K., Faeh, C., & Diederich, F. (2007) · Science · doi:10.1126/science.1131943 · Cited by 6,596
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332
Understanding organofluorine chemistry. An introduction to the C–F bond
O'Hagan, D. (2008) · Chem. Soc. Rev. · doi:10.1039/b711844a · Cited by 4,045
BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
The Many Roles for Fluorine in Medicinal Chemistry
Hagmann, W. K. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800219f · Cited by 3,578
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
Catalysis for fluorination and trifluoromethylation
Furuya, T., Kamlet, A. S., & Ritter, T. (2011) · Nature · doi:10.1038/nature10108 · Cited by 2,215
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
Mendel, D. B., Laird, A., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R., Abrams, T. J., Ngai, T. J., Lee, L. B., et al. (2003) · PubMed · Cited by 1,961
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W., Zhang, C., Zhang, Y., Habets, G., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,831
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2130 · Cited by 1,829
Biocatalytic Asymmetric Synthesis of Chiral Amines from Ketones Applied to Sitagliptin Manufacture
Savile, C. K., Janey, J. M., Mundorff, E. C., Moore, J. C., Tam, S., Jarvis, W. R., Colbeck, J. C., Krebber, A., Fleitz, F. J., Brands, J., et al. (2010) · Science · doi:10.1126/science.1188934 · Cited by 1,756
Fluorine in Medicinal Chemistry and Chemical Biology
(2009) · Wiley eBooks · doi:10.1002/9781444312096 · Cited by 1,731
Organofluorine Chemistry: Principles and Commercial Applications
(1994) · doi:10.1007/978-1-4899-1202-2 · Cited by 1,691
Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways
Sordella, R., Bell, D. W., Haber, D. A., & Settleman, J. (2004) · Science · doi:10.1126/science.1101637 · Cited by 1,606
Fluorinated pyrimidines, a new class of tumour-inhibitory compounds
HEIDELBERGER, C., CHAUDHURI, N. K., DANNEBERG, P., MOOREN, D., GRIESBACH, L., DUSCHINSKY, R., SCHNITZER, R. J., PLEVEN, E., & SCHEINER, J. (1957) · Nature · doi:10.1038/179663a0 · Cited by 1,603
Fluorine in Medicinal Chemistry
Böhm, H., Banner, D., Bendels, S., Kansy, M., Kuhn, B., Müller, K., Obst‐Sander, U., & Stahl, M. (2004) · ChemBioChem · doi:10.1002/cbic.200301023 · Cited by 1,572
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
Wilhelm, S. M., Adnane, L., Newell, P., Villanueva, A., Llovet, J. M., & Lynch, M. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0013 · Cited by 1,459
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White, T. C., Marr, K. A., & Bowden, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.382 · Cited by 1,353
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346
Antifungal agents: mechanisms of action
Odds, F. C., Brown, A. J. P., & Gow, N. A. R. (2003) · Trends in Microbiology · doi:10.1016/s0966-842x(03)00117-3 · Cited by 1,202
Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity
Yun, C.-H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., & Eck, M. J. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.017 · Cited by 1,192
Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity
Dorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M., Mori, J., Rickett, G., Smith-Burchnell, C., Napier, C., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4721-4732.2005 · Cited by 1,152
A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)
Wood, E. R., Truesdale, A. T., McDonald, O. B., Yuan, D., Hassell, A., Dickerson, S. H., Ellis, B., Pennisi, C., Horne, E., Lackey, K., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1168 · Cited by 1,122
Fluorine in medicinal chemistry: A review of anti-cancer agents
Isanbor, C., & O’Hagan, D. (2006) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2006.01.011 · Cited by 1,120
Untitled work
(1991) · PubMed · Cited by 1,101
Enantioselective α-Trifluoromethylation of Aldehydes via Photoredox Organocatalysis
Nagib, D. A., Scott, M. E., & MacMillan, D. W. C. (2009) · Journal of the American Chemical Society · doi:10.1021/ja9053338 · Cited by 988
Organofluorine Compounds: Chemistry and Applications
Hiyama, T. (2000) · Springer eBooks · doi:10.1007/978-3-662-04164-2 · Cited by 950
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
Cui, J. J., Tran-Dubé, M., Shen, H., Nambu, M., Kung, P.-P., Pairish, M., Jia, L., Meng, J., Funk, L., Botrous, I., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2007613 · Cited by 932
Fluorine in medicinal chemistry: Recent therapeutic applications of fluorinated small molecules
Kirk, K. L. (2006) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2006.06.007 · Cited by 900
Update 1 of: Asymmetric Fluorination, Trifluoromethylation, and Perfluoroalkylation Reactions
Ma, J.-A., & Cahard, D. (2008) · Chemical Reviews · doi:10.1021/cr800221v · Cited by 892
Fluorine in health care: Organofluorine containing blockbuster drugs
O’Hagan, D. (2010) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2010.03.003 · Cited by 856
Modern Synthetic Methods for Fluorine‐Substituted Target Molecules
Shimizu, M., & Hiyama, T. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200460441 · Cited by 830
(2 R)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin- 7(8 H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes
Kim, D., Wang, L., Beconi, M., Eiermann, G. J., Fisher, M. H., He, H., Hickey, G. J., Kowalchick, J. E., Leiting, B., Lyons, K., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0493156 · Cited by 822
Bacterial Topoisomerase Inhibitors: Quinolone and Pyridone Antibacterial Agents
Mitscher, L. A. (2005) · Chemical Reviews · doi:10.1021/cr030101q · Cited by 781
1,8-Naphthyridine Derivatives. A New Class of Chemotherapeutic Agents
Lesher, G. Y., Froelich, E. J., Gruett, M. D., Bailey, J. H., & Brundage, R. P. (1962) · Journal of Medicinal and Pharmaceutical Chemistry · doi:10.1021/jm01240a021 · Cited by 766
ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial
Ranson, M., Hammond, L. A., Ferry, D., Kris, M., Tullo, A., Murray, P. I., Miller, V., Averbuch, S., Ochs, J., Morris, C., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.112 · Cited by 763
Innate C-H trifluoromethylation of heterocycles
Ji, Y., Brueckl, T., Baxter, R. D., Fujiwara, Y., Seiple, I. B., Su, S., Blackmond, D. G., & Baran, P. S. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109059108 · Cited by 757
Molecular basis for sunitinib efficacy and future clinical development
Faivre, S., Demetri, G., Sargent, W., & Raymond, E. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2380 · Cited by 721
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
Xia, W., Mullin, R. J., Keith, B. R., Liu, L.-H., Ma, H., Rusnak, D. W., Owens, G., Alligood, K. J., & Spector, N. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205794 · Cited by 664
Capecitabine: A review
Walko, C. M., & Lindley, C. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.01.005 · Cited by 659
Discovery of Raltegravir, a Potent, Selective Orally Bioavailable HIV-Integrase Inhibitor for the Treatment of HIV-AIDS Infection
Summa, V., Petrocchi, A., Bonelli, F., Crescenzi, B., Donghi, M., Ferrara, M., Fiore, F., Gardelli, C., Gonzalez Paz, O., Hazuda, D. J., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800245z · Cited by 633
Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase
LINDSTEDT, S. (1992) · The Lancet · doi:10.1016/0140-6736(92)92685-9 · Cited by 631
Aluminum: a requirement for activation of the regulatory component of adenylate cyclase by fluoride.
Sternweis, P. C., & Gilman, A. G. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.16.4888 · Cited by 624
Recent advances (1995–2005) in fluorinated pharmaceuticals based on natural products
Bégué, J.-P., & Bonnet-Delpon, D. (2006) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2006.05.006 · Cited by 600
On the use of the O-methylmandelate ester for establishment of absolute configuration of secondary alcohols
Trost, B. M., Belletire, J. L., Godleski, S., McDougal, P. G., Balkovec, J. M., Baldwin, J. J., Christy, M. E., Ponticello, G. S., Varga, S. L., & Springer, J. P. (1986) · The Journal of Organic Chemistry · doi:10.1021/jo00362a036 · Cited by 575
Studies leading to the identification of ZD1839 (iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer
Barker, A. J., Gibson, K. H., Grundy, W., Godfrey, A. A., Barlow, J. J., Healy, M. P., Woodburn, J. R., Ashton, S. E., Curry, B. J., Scarlett, L., et al. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00344-4 · Cited by 569
Discovery of 5-[5-Fluoro-2-oxo-1,2- dihydroindol-(3 Z)-ylidenemethyl]-2,4- dimethyl-1 H-pyrrole-3-carboxylic Acid (2-Diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine Kinase
Sun, L., Liang, C., Shirazian, S., Zhou, Y., Miller, T., Cui, J., Fukuda, J. Y., Chu, J.-Y., Nematalla, A., Wang, X., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0204183 · Cited by 521
Predicting and Tuning Physicochemical Properties in Lead Optimization: Amine Basicities
Morgenthaler, M., Schweizer, E., Hoffmann‐Röder, A., Benini, F., Martin, R. E., Jaeschke, G., Wagner, B., Fischer, H., Bendels, S., Zimmerli, D., et al. (2007) · ChemMedChem · doi:10.1002/cmdc.200700059 · Cited by 518
Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues.
Doong, S. L., Tsai, C. H., Schinazi, R. F., Liotta, D. C., & Cheng, Y. C. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.19.8495 · Cited by 516
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention
Christensen, J. G., Burrows, J., & Salgia, R. (2005) · Cancer Letters · doi:10.1016/j.canlet.2004.09.044 · Cited by 513
United States Food and Drug Administration Drug Approval Summary
Cohen, M. H., Williams, G. A., Sridhara, R., Chen, G., McGuinn, W. D., Morse, D., Abraham, S., Rahman, A., Liang, C., Lostritto, R., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0564 · Cited by 503
Prodrug Strategies in Anticancer Chemotherapy
Kratz, F., Müller, I. A., Ryppa, C., & Warnecke, A. (2008) · ChemMedChem · doi:10.1002/cmdc.200700159 · Cited by 486
Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids
Koga, H., Itoh, A., Murayama, S., Suzue, S., & Irikura, T. (1980) · Journal of Medicinal Chemistry · doi:10.1021/jm00186a014 · Cited by 486
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752
Smolen, G. A., Sordella, R., Muir, B., Mohapatra, G., Barmettler, A., Archibald, H., Kim, W. J., Okimoto, R. A., Bell, D. W., Sgroi, D. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508776103 · Cited by 485
AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL
Weisberg, E., Manley, P., Mestan, J., Cowan-Jacob, S., Ray, A., & Griffin, J. D. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603170 · Cited by 484
RECENT ADVANCES IN FLUORINATED PHARMACEUTICALS BASED ON NATURAL PRODUCTS
Hai-tao, Y. (2006) · Cited by 483
Biosynthesis of an organofluorine molecule
O'Hagan, D., Schaffrath, C., Cobb, S. L., Hamilton, J. T. G., & Murphy, C. D. (2002) · Nature · doi:10.1038/416279a · Cited by 449
Type II photoelimination and photocyclization of ketones
Wagner, P. J. (1971) · Accounts of Chemical Research · doi:10.1021/ar50041a002 · Cited by 441
Fluorinated Carbonyl and Olefinic Compounds: Basic Character and Asymmetric Catalytic Reactions
Mikami, K., Itoh, Y., & Yamanaka, M. (2003) · Chemical Reviews · doi:10.1021/cr030685w · Cited by 437
Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension
Netland, P. A., Landry, T., Sullivan, E. K., Andrew, R., Silver, L., Weiner, A., Mallick, S., Dickerson, J., Bergamini, M. V. W., Robertson, S. M., et al. (2001) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(01)01177-1 · Cited by 417
RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models
Yang, H., Higgins, B., Kolinsky, K., Packman, K., Go, Z., Iyer, R., Kolis, S., Zhao, S., Lee, R., Grippo, J. F., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0646 · Cited by 407
Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 2. Clinical Considerations and New Agents
Jordan, V. C. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020450x · Cited by 396
New approaches to molecular cancer therapeutics
Collins, I., & Workman, P. (2006) · Nature Chemical Biology · doi:10.1038/nchembio840 · Cited by 391
Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): A review
Malet-Martino, M., & Martino, R. (2002) · The Oncologist · doi:10.1634/theoncologist.7-4-288 · Cited by 382
Discovery of 1-(4-Fluorophenyl)-(3 R)-[3-(4-fluorophenyl)-(3 S)- hydroxypropyl]-(4 S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption
Rosenblum, S. B., Huynh, T., Afonso, A., Davis, H. R., Yumibe, N., Clader, J. W., & Burnett, D. A. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm970701f · Cited by 361
Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy
Ciardiello, F., Bianco, R., Caputo, R., Caputo, R., Damiano, V., Troiani, T., Melisi, D., De Vita, F., De Placido, S., Bianco, A. R., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1100-03 · Cited by 347
Crystal structure and mechanism of a bacterial fluorinating enzyme
Dong, C., Huang, F., Deng, H., Schaffrath, C., Spencer, J. B., O'Hagan, D., & Naismith, J. H. (2004) · Nature · doi:10.1038/nature02280 · Cited by 335
The Discovery of Ezetimibe: A View from Outside the Receptor
Clader, J. W. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030283g · Cited by 325
The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer
Hyttel, J., B�ges�, K. P., Perregaard, J., & S�nchez, C. (1992) · Journal of Neural Transmission · doi:10.1007/bf01244820 · Cited by 323
9α-FLUORO DERIVATIVES OF CORTISONE AND HYDROCORTISONE
Fried, J., & Sabo, E. F. (1954) · Journal of the American Chemical Society · doi:10.1021/ja01634a101 · Cited by 323
Fluorine-containing natural products
O’Hagan, D., & B. Harper, D. (1999) · Journal of Fluorine Chemistry · doi:10.1016/s0022-1139(99)00201-8 · Cited by 318
Highly Efficient Asymmetric Synthesis of Sitagliptin
Hansen, K. B., Hsiao, Y., Xu, F., Rivera, N., Clausen, A., Kubryk, M., Krska, S., Rosner, T., Simmons, B., Balsells, J., et al. (2009) · Journal of the American Chemical Society · doi:10.1021/ja902462q · Cited by 314
Novel 4-Anilinoquinazolines with C-7 Basic Side Chains: Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors
Hennequin, L. F., Stokes, E. S. E., Thomas, A. P., Johnstone, C., Plé, P. A., Ogilvie, D. J., Dukes, M., Wedge, S. R., Kendrew, J., & Curwen, J. O. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm011022e · Cited by 311
The role of substance P in stress and anxiety responses
Ebner, K., & Singewald, N. (2006) · Amino Acids · doi:10.1007/s00726-006-0335-9 · Cited by 306
Dual Kinase Inhibition in the Treatment of Breast Cancer: Initial Experience with the EGFR/ErbB-2 Inhibitor Lapatinib
Burris, H. A. (2004) · The Oncologist · doi:10.1634/theoncologist.9-suppl_3-10 · Cited by 295
Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
Schinazi, R. F., McMillan, A., Cannon, D., Mathis, R., Lloyd, R. M., Peck, A., Sommadossi, J. P., St Clair, M., Wilson, J., & Furman, P. A. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.11.2423 · Cited by 294
Antagonists of the Platelet P2T Receptor: A Novel Approach to Antithrombotic Therapy
Ingall, A. H., Dixon, J., Bailey, A., Coombs, M. E., Cox, D., McInally, J. I., Hunt, S. F., Kindon, N. D., Teobald, B. J., Willis, P. A., et al. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm981072s · Cited by 283
Azasteroids: structure-activity relationships for inhibition of 5.alpha.-reductase and of androgen receptor binding
Rasmusson, G. H., Reynolds, G. F., Steinberg, N. G., Walton, E., Patel, G. F., Liang, T., Cascieri, M. A., Cheung, A. H., Brooks, J. R., & Berman, C. (1986) · Journal of Medicinal Chemistry · doi:10.1021/jm00161a028 · Cited by 255
Escitalopram versus citalopram: the surprising role of the R-enantiomer
S�nchez, C., B�ges�, K., Ebert, B., Reines, E., & Braestrup, C. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1865-z · Cited by 248
Design and Structure−Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors
Hennequin, L. F., Thomas, A. P., Johnstone, C., Stokes, E. S. E., Plé, P. A., Lohmann, J.-J. M., Ogilvie, D. J., Dukes, M., Wedge, S. R., Curwen, J. O., et al. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm990345w · Cited by 241
[123I]-2.beta.-carbomethoxy-3.beta.-(4-iodophenyl)tropane: high-affinity SPECT (single photon emission computed tomography) radiotracer of monoamine reuptake sites in brain
Neumeyer, J. L., Wang, S., Milius, R. A., Baldwin, R. M., Zea-Ponce, Y., Hoffer, P. B., Sybirska, E., Al-Tikriti, M., & Charney, D. S. (1991) · Journal of Medicinal Chemistry · doi:10.1021/jm00114a027 · Cited by 239
From ATP to AZD6140: The discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis
Springthorpe, B., Bailey, A., Barton, P., Birkinshaw, T. N., Bonnert, R. V., Brown, R. C., Chapman, D., Dixon, J., Guile, S. D., Humphries, R. G., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.07.057 · Cited by 235
Herbicidal 4-hydroxyphenylpyruvate dioxygenase inhibitors—A review of the triketone chemistry story from a Syngenta perspective
Beaudegnies, R., Edmunds, A. J. F., Fraser, T. E. M., Hall, R. G., Hawkes, T. R., Mitchell, G., Schaetzer, J., Wendeborn, S., & Wibley, J. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.03.015 · Cited by 230
KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues.
Shibata, K., Foglar, R., Horie, K., Obika, K., Sakamoto, A., Ogawa, S., & Tsujimoto, G. (1995) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10243-5 · Cited by 228
Remarkable Amplification of the Self‐Disproportionation of Enantiomers on Achiral‐Phase Chromatography Columns
Soloshonok, V. A. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200503373 · Cited by 227
Self-citation
An overview on 5α-reductase inhibitors
Aggarwal, S., Thareja, S., Verma, A., Bhardwaj, T. R., & Kumar, M. (2010) · Steroids · doi:10.1016/j.steroids.2009.10.005 · Cited by 223
Nilotinib (AMN107, Tasigna®) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters
Tiwari, A. K., Sodani, K., Wang, S.-R., Kuang, Y.-H., Ashby, C. R., Chen, X., & Chen, Z.-S. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.04.002 · Cited by 209
Structural Optimization Affording 2-(R)-(1-(R)-3,5-Bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a Potent, Orally Active, Long-Acting Morpholine Acetal Human NK-1 Receptor Antagonist
Hale, J. J., Mills, S. G., MacCoss, M., Finke, P. E., Cascieri, M. A., Sadowski, S., Ber, E., Chicchi, G. G., Kurtz, M., Metzger, J., et al. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm980299k · Cited by 207
Series Introduction: Invasive growth: from development to metastasis
Comoglio, P. M., & Trusolino, L. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15392 · Cited by 200
Exploration of Fluorine Chemistry at the Multidisciplinary Interface of Chemistry and Biology
Ojima, I. (2013) · The Journal of Organic Chemistry · doi:10.1021/jo400301u · Cited by 198
Recent Advances in the Synthesis of Fluorinated Amino Acids
Qiu, X., & Qing, F. (2011) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201100032 · Cited by 196
Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions
Morabito, A., Piccirillo, M. C., Falasconi, F., De Feo, G., Del Giudice, A., Bryce, J., Di Maio, M., De Maio, E., Normanno, N., & Perrone, F. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0261 · Cited by 196
Similarities and distinctions in the mode of action of different classes of antioestrogens.
Wakeling, A. E. (2000) · Endocrine-related cancer · doi:10.1677/erc.0.0070017 · Cited by 193
The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects
Cattaneo, M. (2011) · Blood · doi:10.1182/blood-2010-08-263111 · Cited by 191
Hydration of the fluoride anion: structures and absolute hydration free energy from first-principles electronic structure calculations
Zhan, C.-G., & Dixon, D. A. (2004) · The Journal of Physical Chemistry A · doi:10.1021/jp0311512 · Cited by 191
The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: A structural analysis of the binding interactions of Gleevec®, Nexavar®, and BIRB-796
Dietrich, J., Hulme, C., & Hurley, L. H. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.05.063 · Cited by 188
Phenomenon of Optical Self-Purification of Chiral Non-Racemic Compounds
Soloshonok, V. A., Ueki, H., Yasumoto, M., Mekala, S., Hirschi, J. S., & Singleton, D. A. (2007) · Journal of the American Chemical Society · doi:10.1021/ja065603a · Cited by 187
Self-citation
SYNTHESIS OF 17α-HYDROXYCORTICOSTERONE AND ITS 9α-HALO DERIVATIVES FROM 11-EPI-17α-HYDROXYCORTICOSTERONE
Fried, J., & Sabo, E. F. (1953) · Journal of the American Chemical Society · doi:10.1021/ja01105a527 · Cited by 181
ZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activity
Ryan, A. J., & Wedge, S. R. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602603 · Cited by 177
Laser flash photolysis studies of the reactions of some 1,4-biradicals
Scaiano, J. C. (1982) · Accounts of Chemical Research · doi:10.1021/ar00080a004 · Cited by 175
Lapatinib: A novel EGFR/HER2 tyrosine kinase inhibitor for cancer
Johnston, S. R. D., & Leary, A. (2006) · Drugs of Today · doi:10.1358/dot.2006.42.7.985637 · Cited by 174
Series Introduction: Invasive growth: from development to metastasis
Comoglio, P. M., & Trusolino, L. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215392 · Cited by 174
Advances in synthetic approach to and antifungal activity of triazoles
Shalini, K., Kumar, N., Drabu, S., & Sharma, P. K. (2011) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.7.79 · Cited by 173
Pharmacological Options in the Treatment of Benign Prostatic Hyperplasia
Kenny, B., Ballard, S., Blagg, J., & Fox, D. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm960697s · Cited by 169
Recent Advances in the Asymmetric Synthesis of α-(Trifluoromethyl)-Containing α-Amino Acids
Aceña, J., Soloshonok, V., & Sorochinsky, A. (2012) · Synthesis · doi:10.1055/s-0031-1289756 · Cited by 168
Self-citation
Synthesis and Biological Activity of Methanesulfonamide Pyrimidine- and N-Methanesulfonyl Pyrrole-Substituted 3,5-Dihydroxy-6-heptenoates, a Novel Series of HMG-CoA Reductase Inhibitors
Watanabe, M., Koike, H., Ishiba, T., Okada, T., Seo, S., & Hirai, K. (1997) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(96)00248-9 · Cited by 167
First Generation Process for the Preparation of the DPP-IV Inhibitor Sitagliptin
Hansen, K. B., Balsells, J., Dreher, S., Hsiao, Y., Kubryk, M., Palucki, M., Rivera, N., Steinhuebel, D., Armstrong, J. D., Askin, D., et al. (2005) · Organic Process Research & Development · doi:10.1021/op0500786 · Cited by 167
Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series
Petrov, K. G., Zhang, Y.-M., Carter, M., Cockerill, G. S., Dickerson, S., Gauthier, C. A., Guo, Y., Mook, R. A., Rusnak, D. W., Walker, A. L., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.05.090 · Cited by 166
Biosynthesis of fluorothreonine and fluoroacetic acid by the thienamycin producer, Streptomyces cattleya.
SANADA, M., MIYANO, T., IWADARE, S., WILLIAMSON, J. M., ARISON, B. H., SMITH, J. L., DOUGLAS, A. W., LIESCH, J. M., & INAMINE, E. (1986) · The Journal of Antibiotics · doi:10.7164/antibiotics.39.259 · Cited by 166
N-.omega.-Fluoroalkyl Analogs of (1R)-2.beta.-Carbomethoxy-3.beta.-(4-iodophenyl)tropane (.beta.-CIT): Radiotracers for Positron Emission Tomography and Single Photon Emission Computed Tomography Imaging of Dopamine Transporters
Neumeyer, J. L., Campbell, A., Wang, S., Gao, Y., Milius, R. A., Kula, N. S., Baldessarini, R. J., Zea-Ponce, Y., Baldwin, R. M., & Innis, R. B. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00037a004 · Cited by 164
Self-disproportionation of enantiomers via achiral chromatography: a warning and an extra dimension in optical purifications
Soloshonok, V. A., Roussel, C., Kitagawa, O., & Sorochinsky, A. E. (2012) · Chemical Society Reviews · doi:10.1039/c2cs35006h · Cited by 163
Self-citation
Efficient Synthesis of NK1 Receptor Antagonist Aprepitant Using a Crystallization-Induced Diastereoselective Transformation
Brands, K. M. J., Payack, J. F., Rosen, J. D., Nelson, T. D., Candelario, A., Huffman, M. A., Zhao, M. M., Li, J., Craig, B., Song, Z. J., et al. (2003) · Journal of the American Chemical Society · doi:10.1021/ja027458g · Cited by 159
Chromenes through Metal-Catalyzed Reactions of Styrenyl Ethers. Mechanism and Utility in Synthesis
Harrity, J. P. A., La, D. S., Cefalo, D. R., Visser, M. S., & Hoveyda, A. H. (1998) · Journal of the American Chemical Society · doi:10.1021/ja9739796 · Cited by 159
Absorption, Metabolism, and Excretion of Paliperidone, a New Monoaminergic Antagonist, in Humans
Vermeir, M., Naessens, I., Remmerie, B., Mannens, G., Hendrickx, J., Sterkens, P., Talluri, K., Boom, S., Eerdekens, M., van Osselaer, N., et al. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.018275 · Cited by 158
Lapatinib
Moy, B., Kirkpatrick, P. N., Kar, S., & Goss, P. E. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2332 · Cited by 157
Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib
Manley, P. W., Stiefl, N., Cowan‐Jacob, S. W., Kaufman, S., Mestan, J., Wartmann, M., Wiesmann, M., Woodman, R., & Gallagher, N. J. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.08.026 · Cited by 153
Nitisinone in the Treatment of Hereditary Tyrosinaemia Type 1
McKiernan, P. J. (2006) · Drugs · doi:10.2165/00003495-200666060-00002 · Cited by 153
Asymmetric synthesis of fluorine-containing amines, amino alcohols, α- and β-amino acids mediated by chiral sulfinyl group
Sorochinsky, A. E., & Soloshonok, V. A. (2009) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2009.09.015 · Cited by 153
Self-citation
Natural products and Pharma 2011: Strategic changes spur new opportunities
Carter, G. T. (2011) · Natural Product Reports · doi:10.1039/c1np00033k · Cited by 144
Selective PDE inhibitors as novel treatments for respiratory diseases
Page, C. P., & Spina, D. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.02.016 · Cited by 143
2-Azetidinone Cholesterol Absorption Inhibitors: Structure−Activity Relationships on the Heterocyclic Nucleus
Clader, J. W., Burnett, D. A., Caplen, M. A., Domalski, M. S., Dugar, S., Vaccaro, W. D., Sher, R., Browne, M. E., Zhao, H., Burrier, R. E., et al. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm960405n · Cited by 133
Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical Candidates
Underiner, T. L., Herbertz, T., & Miknyoczki, S. J. (2010) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520611009010007 · Cited by 133
Pharmacological and clinical properties of calcimimetics: Calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism
Nagano, N. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.06.019 · Cited by 131
Asymmetric synthesis and biological evaluation of .beta.-L-(2R,5S)- and .alpha.-L-(2R,5R)-1,3-oxathiolane-pyrimidine and -purine nucleosides as potential anti-HIV agents
Jeong, L. S., Schinazi, R. F., Beach, J. W., Kim, H. O., Nampalli, S., Shanmuganathan, K., Alves, A. J., McMillan, A., Chu, C. K., & Mathis, R. (1993) · Journal of Medicinal Chemistry · doi:10.1021/jm00054a001 · Cited by 130
MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations
Tanizaki, J., Okamoto, I., Okamoto, K., Takezawa, K., Kuwata, K., Yamaguchi, H., & Nakagawa, K. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31822591e9 · Cited by 129
Current and Novel Approaches to the Drug Treatment of Schizophrenia
Rowley, M., Bristow, L. J., & Hutson, P. H. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0002432 · Cited by 128
A Selective Small Molecule c-MET Inhibitor, PHA665752, Cooperates with Rapamycin
Ma, P. C., Schaefer, E., Christensen, J. G., & Salgia, R. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1708 · Cited by 124
Conazoles
Heeres, J., Meerpoel, L., & Lewi, P. J. (2010) · Molecules · doi:10.3390/molecules15064129 · Cited by 124
Practical Synthesis of Fluorine-Containing α- and β-Amino Acids: Recipes from Kiev, Ukraine
Kukhar, V. P., Sorochinsky, A. E., & Soloshonok, V. A. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.70 · Cited by 121
Self-citation
The Met pathway: master switch and drug target in cancer progression
Mazzone, M., & Comoglio, P. M. (2006) · The FASEB Journal · doi:10.1096/fj.06-5947rev · Cited by 120
Escitalopram
Murdoch, D. R., & Keam, S. J. (2005) · Drugs · doi:10.2165/00003495-200565160-00013 · Cited by 117
A Scaleable Synthesis of BAY 43-9006: A Potent Raf Kinase Inhibitor for the Treatment of Cancer
Bankston, D. D., Dumas, J., Natero, R., et al. (2002) · Organic Process Research & Development · doi:10.1021/op020205n · Cited by 115
3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as High Affinity, Selective, and Orally Bioavailable h5-HT2A Receptor Antagonists
Rowley, M., Hallett, D. J., Goodacre, S. C., Moyes, C. R., Crawforth, J. M., Sparey, T. J., Patel, S. S., Marwood, R., Patel, S., Thomas, S., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0004998 · Cited by 114
Voriconazole: therapeutic review of a new azole antifungal
Herbrecht, R. (2004) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2.4.485 · Cited by 113
The search for new triazole antifungal agents
Koltin, Y., & Hitchcock, C. A. (1997) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(97)80007-5 · Cited by 110
From toxicological problem to therapeutic use: The discovery of the mode of action of 2‐(2‐nitro‐4‐trifluoromethylbenzoyl)‐1,3‐cyclohexanedione (NTBC), its toxicology and development as a drug
Lock, E. A., Ellis, M. K., Gaskin, P., Robinson, M., Auton, T. R., Provan, W. M., Smith, L. L., Prisbylla, M. P., Mutter, L. C., & Lee, D. L. (1998) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1005458703363 · Cited by 109
Biomimetic Transamination – a Metal-Free Alternative to the Reductive Amination. Application for Generalized Preparation of Fluorine-Containing Amines and Amino Acids
Han, J., Sorochinsky, A. E., Ono, T., & Soloshonok, V. A. (2011) · Current Organic Synthesis · doi:10.2174/157017911794697277 · Cited by 109
Self-citation
Rational application of self-disproportionation of enantiomers via sublimation—a novel methodological dimension for enantiomeric purifications
Ueki, H., Yasumoto, M., & Soloshonok, V. A. (2010) · Tetrahedron Asymmetry · doi:10.1016/j.tetasy.2010.04.040 · Cited by 108
Self-citation
Nebivolol: A Highly Selective β1‐Adrenergic Receptor Blocker That Causes Vasodilation by Increasing Nitric Oxide
Gupta, S., & Wright, H. M. (2008) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2008.00054.x · Cited by 107
Molecular genetic analysis of azole antifungal mode of action
Kelly, S. L., Arnoldi, A., & Kelly, D. E. (1993) · Biochemical Society Transactions · doi:10.1042/bst0211034 · Cited by 106
Mutational Mapping and Modeling of the Binding Site for (S)-Citalopram in the Human Serotonin Transporter
Andersen, J., Olsen, L., Hansen, K. B., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.072587 · Cited by 105
Self-Disproportionation of Enantiomers via Sublimation; New and Truly Green Dimension in Optical Purification
Han, J., Nelson, D. J., Sorochinsky, A. E., & Soloshonok, V. A. (2011) · Current Organic Synthesis · doi:10.2174/157017911794697303 · Cited by 101
Self-citation
Formulation of an ophthalmic lipid emulsion containing an anti-inflammatory steroidal drug, difluprednate
Yamaguchi, M., Yasueda, S.-I., Isowaki, A., Yamamoto, M., Kimura, M., Inada, K., & Ohtori, A. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.05.036 · Cited by 100
Novel Chimeric Histone Deacetylase Inhibitors: A Series of Lapatinib Hybrides as Potent Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and Histone Deacetylase Activity
Mahboobi, S., Sellmer, A., Winkler, M., Eichhorn, E., Pongratz, H., Ciossek, T., Baer, T., Maier, T. M., & Beckers, T. L. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100665z · Cited by 99
Optical Purifications via Self‐Disproportionation of Enantiomers by Achiral Chromatography: Case Study of a Series of α‐CF3‐containing Secondary Alcohols
Sorochinsky, A. E., Katagiri, T., Ono, T., Wzorek, A., Aceña, J. L., & Soloshonok, V. A. (2013) · Chirality · doi:10.1002/chir.22180 · Cited by 99
Self-citation
Self-disproportionation of enantiomers of (R)-ethyl 3-(3,5-dinitrobenzamido)-4,4,4-trifluorobutanoate on achiral silica gel stationary phase
Soloshonok, V. A., & Berbasov, D. O. (2006) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2005.11.004 · Cited by 98
Self-citation
Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase
Wang, J.-Q., Gao, M., Miller, K. D., Sledge, G. W., & Zheng, Q. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.04.080 · Cited by 97
Self-citation
Asymmetric aldol reactions of trifluoromethyl ketones with a chiral Ni(II) complex of glycine: Stereocontrolling effect of the trifluoromethyl group
Soloshonok, V. A., Avilov, D. V., & Kukhar, V. P. (1996) · Tetrahedron · doi:10.1016/0040-4020(96)00741-7 · Cited by 96
Self-citation
Highly diastereoselective aldol reaction of fluoroalkyl aryl ketones with methyl isocyanoacetate catalyzed by silver(I)/triethylamine
Soloshonok, V. A., Hayashi, T., Ishikawa, K., & Nagashima, N. (1994) · Tetrahedron Letters · doi:10.1016/s0040-4039(00)79964-3 · Cited by 94
Self-citation
Development of a Bulk Enabling Route to Maraviroc (UK-427,857), a CCR-5 Receptor Antagonist
Haycock-Lewandowski, S. J., Wilder, A., & Åhman, J. (2008) · Organic Process Research & Development · doi:10.1021/op8000614 · Cited by 93
Lessons from the Drug Discovery of Lapatinib, a Dual ErbB1/2 Tyrosine Kinase Inhibitor
Lackey, K. E. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606776743156 · Cited by 92
Fit-for-Purpose Development of the Enabling Route to Crizotinib (PF-02341066)
de Koning, P. D., McAndrew, D., Moore, R., Moses, I. B., Boyles, D. C., Kissick, K., Stanchina, C. L., Cuthbertson, T. J., Kamatani, A., Rahman, L. T., et al. (2011) · Organic Process Research & Development · doi:10.1021/op200131n · Cited by 92
Emtricitabine, a New Antiretroviral Agent with Activity against HIV and Hepatitis B Virus
Saravolatz, L. D., & Saag, M. S. (2005) · Clinical Infectious Diseases · doi:10.1086/498348 · Cited by 91
Voriconazole: A second-generation triazole
Chandrasekar, P. H., & Manavathu, E. K. (2001) · Drugs of today · doi:10.1358/dot.2001.37.2.614849 · Cited by 91
Self-Disproportionation of Enantiomers of Chiral, Non-Racemic Fluoroorganic Compounds: Role of Fluorine as Enabling Element
Soloshonok, V. A., Sorochinsky, A. E., & Aceña, J. L. (2012) · Synthesis · doi:10.1055/s-0032-1316812 · Cited by 90
Self-citation
Synthesis and biological evaluations of quinoline-based HMG-CoA reductase inhibitors
Suzuki, M., Iwasaki, H., Fujikawa, Y., Kitahara, M., Sakashita, M., & Sakoda, R. (2001) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(01)00198-5 · Cited by 88
Biosynthesis of the Marine Cyanobacterial Metabolite Barbamide. 1. Origin of the Trichloromethyl Group
Sitachitta, N., Rossi, J. V., Roberts, M. A., et al. (1998) · Journal of the American Chemical Society · doi:10.1021/ja9811389 · Cited by 86
Do Substance P and the NK1 Receptor have a Role in Depression and Anxiety?
McLean, S. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612053764779 · Cited by 85
Discovery and Development of Small-Molecule Chemokine Coreceptor CCR5 Antagonists
Palani, A., & Tagat, J. R. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060009x · Cited by 85
Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification
Okamoto, W., Okamoto, I., Arao, T., Kuwata, K., Hatashita, E., Yamaguchi, H., Sakai, K., Yanagihara, K., Nishio, K., & Nakagawa, K. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0934 · Cited by 85
Novel antifungal 2-aryl-1-(1H-1,2,4-triazol-1-yl)butan-2-ol derivatives with high activity against Aspergillus fumigatus
DICKINSON, R. P., Bell, A., Hitchcock, C. A., Narayanaswami, S., Ray, S. J., Richardson, K., & Troke, P. F. (1996) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/0960-894x(96)00363-0 · Cited by 85
Gold(I)-catalyzed asymmetric aldol reactions of isocyanoacetic acid derivatives with fluoroaryl aldehydes
Soloshonok, V. A., Kacharov, A. D., & Hayashi, T. (1996) · Tetrahedron · doi:10.1016/0040-4020(95)00893-d · Cited by 83
Self-citation
The Two Enantiomers of Citalopram Bind to the Human Serotonin Transporter in Reversed Orientations
Koldsø, H., Severinsen, K., Tran, T. T. T., et al. (2010) · Journal of the American Chemical Society · doi:10.1021/ja906923j · Cited by 83
Dihydroxypyrimidine-4-carboxamides as Novel Potent and Selective HIV Integrase Inhibitors
Pace, P., Francesco, M. E. D., Gardelli, C., Harper, S., Muraglia, E., Nizi, E., Orvieto, F., Petrocchi, A., Poma, M., Rowley, M., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070027u · Cited by 80
Interactions between antiepileptics and second-generation antipsychotics
de León, J., Santoro, V., D’Arrigo, C., & Spina, E. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.660918 · Cited by 79
PDE4: A Novel Target in the Treatment of Chronic Obstructive Pulmonary Disease
Michalski, J., Golden, G. A., Ikari, J., & Rennard, S. I. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.266 · Cited by 78
Rosuvastatin
Carswell, C., Plosker, G. L., & Jarvis, B. (2002) · Drugs · doi:10.2165/00003495-200262140-00008 · Cited by 78
Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc
Price, D. A., Armour, D. R., de Groot, M. J., Leishman, D. J., Napier, C. M., Perros, M., Stammen, B., & Wood, A. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.06.012 · Cited by 77
Anaplastic lymphoma kinase-directed therapy in inflammatory myofibroblastic tumors
Tóthová, Z., & Wagner, A. J. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328354c155 · Cited by 77
Fluorine in medicine
Strunecká, A., Patočka, J., & Connett, P. H. (2004) · Journal of Applied Biomedicine · doi:10.32725/jab.2004.017 · Cited by 77
From the Selective Serotonin Transporter Inhibitor Citalopram to the Selective Norepinephrine Transporter Inhibitor Talopram: Synthesis and Structure−Activity Relationship Studies
Eildal, J. N. N., Andersen, J., Kristensen, A. S., Jørgensen, A. M., Bang‐Andersen, B., Jørgensen, M., & Strømgaard, K. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701602g · Cited by 76
Discovery and Clinical Development of Dutasteride, a Potent Dual 5α- Reductase Inhibitor
Frye, S. V. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606776743101 · Cited by 74
Recent Developments in the Design of Anti-Depressive Therapies: Targeting the Serotonin Transporter
Butler, S., & Meegan, M. J. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708784872357 · Cited by 70
Rosuvastatin in the management of hyperlipidemia
Cheng, J. W. M. (2004) · Clinical Therapeutics · doi:10.1016/j.clinthera.2004.09.005 · Cited by 69
Synthesis and biological activity of new HMG-CoA reductase inhibitors. 1. Lactones of pyridine- and pyrimidine-substituted 3,5-dihydroxy-6-heptenoic (-heptanoic) acids
Beck, G., Keßeler, K., Baader, E., Bartmann, W., Bergmann, A., Granzer, E., Jendralla, H., Kerékjártó, B. V., & Krause, R. (1990) · Journal of Medicinal Chemistry · doi:10.1021/jm00163a010 · Cited by 68
Interaction of (4-Hydroxyphenyl)pyruvate Dioxygenase with the Specific Inhibitor 2-[2-Nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione
Kavana, M., & Moran, G. R. (2003) · Biochemistry · doi:10.1021/bi034658b · Cited by 68
Nebivolol: A Review of its Use in the Management of Hypertension and Chronic Heart Failure
Moen, M. D., & Wagstaff, A. J. (2006) · Drugs · doi:10.2165/00003495-200666100-00007 · Cited by 68
Discovery and Synthesis of HIV Integrase Inhibitors: Development of Potent and Orally Bioavailable N-Methyl Pyrimidones
Gardelli, C., Nizi, E., Muraglia, E., Crescenzi, B., Ferrara, M., Orvieto, F., Pace, P., Pescatore, G., Poma, M., Ferreira, M. D. R. R., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0704705 · Cited by 67
The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib
Deadman, B. J., Hopkin, M. D., Baxendale, I. R., & Ley, S. V. (2012) · Organic & Biomolecular Chemistry · doi:10.1039/c2ob27003j · Cited by 65
Self-disproportionation of enantiomers of isopropyl 3,3,3-(trifluoro)lactate via sublimation: Sublimation rates vs. enantiomeric composition
Yasumoto, M., Ueki, H., Ono, T., Katagiri, T., & Soloshonok, V. A. (2009) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2009.11.026 · Cited by 64
Self-citation
Biomarkers in Parkinsonʼs disease: an update
Shtilbans, A., & Henchcliffe, C. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283550c0d · Cited by 63
Allosteric Inhibitor Development Targeting HIV‐1 Integrase
Al‐Mawsawi, L. Q., & Neamati, N. (2011) · ChemMedChem · doi:10.1002/cmdc.201000443 · Cited by 63
Self-disproportionation of enantiomers of 3,3,3-trifluorolactic acid amides via sublimation
Yasumoto, M., Ueki, H., & Soloshonok, V. A. (2009) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2009.10.002 · Cited by 61
Self-citation
Nebivolol
Otto Kamp, B., Metra, M., Bugatti, S., Bettari, L., Dei, A., Petrini, N., & Cas, L. D. (2009) · Drugs · doi:10.2165/11530710-000000000-00000 · Cited by 60
Maraviroc
Carter, N. J., & Keating, G. M. (2007) · Drugs · doi:10.2165/00003495-200767150-00010 · Cited by 60
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors
Polyzos, A. (2007) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2007.09.004 · Cited by 59
Inhibitors of the anaplastic lymphoma kinase
Mologni, L. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.690031 · Cited by 58
Kv7 Channels as Targets for the Treatment of Pain
Wickenden, A., & McNaughton-Smith, G. A. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788186326 · Cited by 53
An Improved and Scalable Process for the Synthesis of Ezetimibe: An Antihypercholesterolemia Drug
Sasikala, C. V. A., Padi, P. R., Sunkara, V., Ramayya, P., Dubey, P. K., Uppala, V. B. R., & Praveen, C. (2009) · Organic Process Research & Development · doi:10.1021/op900039z · Cited by 50
An efficient synthesis of rufinamide, an antiepileptic drug
Mudd, W. H., & Stevens, E. P. (2010) · Tetrahedron Letters · doi:10.1016/j.tetlet.2010.04.060 · Cited by 49
New atypical antipsychotics for schizophrenia: iloperidone
Caccia, S. (2010) · Drug Design Development and Therapy · doi:10.2147/dddt.s6443 · Cited by 49
Chirality-dependent sublimation of -(trifluoromethyl)-lactic acid: Relative vapor pressures of racemic, eutectic, and enantiomerically pure forms, and vibrational spectroscopy of isolated (S,S) and (S,R) dimers
Albrecht, M., Soloshonok, V. A., Schrader, L., Yasumoto, M., & Suhm, M. A. (2009) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2009.11.015 · Cited by 48
Self-citation
SU11248 (sunitinib) directly inhibits the activity of mammalian 5'-AMP-activated protein kinase (AMPK)
Laderoute, K. R., Calaoagan, J. M., Madrid, P. B., Klon, A. E., & Ehrlich, P. J. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.1.12162 · Cited by 48
Structure-Activity Relationships for Inhibition of Type 1 and 2 Human 5.alpha.-Reductase and Human Adrenal 3.beta.-Hydroxy-.DELTA.5-steroid Dehydrogenase/3-Keto-.DELTA.5-steroid Isomerase by 6-Azaandrost-4-en-3-ones: Optimization of the C17 Substituent
Frye, S. V., Haffner, C. D., Maloney, P., Hiner, R. N., Dorsey, G. F., Noe, R. A., Unwalla, R. J., Batchelor, K. W., Bramson, H. N., Stuart, J. D., et al. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00014a015 · Cited by 48
Rapid Continuous Synthesis of 5′-Deoxyribonucleosides in Flow via Brønsted Acid Catalyzed Glycosylation
Shen, B., & Jamison, T. F. (2012) · Organic Letters · doi:10.1021/ol301324g · Cited by 48
Recent Advances in Antifungal Agents
Lóránd, T., & Kocsis, B. (2007) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955707781662672 · Cited by 47
From dihydroxypyrimidine carboxylic acids to carboxamide HIV-1 integrase inhibitors: SAR around the amide moiety
Petrocchi, A., Koch, U., Matassa, V. G., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.10.054 · Cited by 47
Self-disproportionation of enantiomers of α-trifluoromethyl lactic acid amides via sublimation
Yasumoto, M., Ueki, H., & Soloshonok, V. A. (2009) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2009.11.010 · Cited by 45
Self-citation

Research works printed but not linked: 301

Christe K. O., 1986, Inorg. Chem., 25, 3721, 10.1021/ic00241a001 · doi:10.1021/ic00241a001
Moissan H., 1896, C. R. Hebd. Acad. Sci., 128, 1543
Ruff O., 1930, Z. Anorg. Allg. Chem., 190, 270, 10.1002/zaac.19301900127 · doi:10.1002/zaac.19301900127
Baasner B., 2000, Houben-Weyl Methods of Organic Chemistry, 10
Marais J. S. C., 1943, Onderstepoort J. Vet. Sci. Anim. Ind., 18, 203
Marais J. S. C., 1944, Onderstepoort J. Vet. Sci. Anim. Ind., 20, 67
Gribble G. W., 2004, J. Chem. Educ., 81, 1441, 10.1021/ed081p1441 · doi:10.1021/ed081p1441
Fuchikami T., 1982, Tetrahedron Lett., 23, 4099, 10.1016/S0040-4039(00)88357-4 · doi:10.1016/s0040-4039(00)88357-4
Ojima I., 1987, J. Am. Chem. Soc., 109, 7714, 10.1021/ja00259a020 · doi:10.1021/ja00259a020
Ojima I., 1988, J. Am. Chem. Soc., 110, 150, 10.1021/ja00209a024 · doi:10.1021/ja00209a024
Ojima I., 1989, J. Org. Chem., 54, 4511, 10.1021/jo00280a014 · doi:10.1021/jo00280a014
Soloshonok V. A., 1994, Tetrahedron Lett., 35, 5063, 10.1016/S0040-4039(00)73320-X · doi:10.1016/s0040-4039(00)73320-x
Katagiri T., 2001, Chem. Commun., 2054, 10.1039/b105602f · doi:10.1039/b105602f
Fuchikami T., 1982, J. Am. Chem. Soc., 104, 3527, 10.1021/ja00376a057 · doi:10.1021/ja00376a057
Fuchikami T., 1983, J. Org. Chem., 48, 3803, 10.1021/jo00169a040 · doi:10.1021/jo00169a040
Ojima I., 1988, J. Am. Chem. Soc., 110, 5617, 10.1021/ja00225a004 · doi:10.1021/ja00225a004
Soloshonok V. A., 1994, Tetrahedron Lett., 35, 2713, 10.1016/S0040-4039(00)77013-4 · doi:10.1016/s0040-4039(00)77013-4
Soloshonok V. A., 1994, Tetrahedron: Asymmetry, 5, 1091, 10.1016/0957-4166(94)80059-6 · doi:10.1016/0957-4166(94)80059-6
Kobzev S. V., 1989, Zh. Obshch. Khim., 59, 909
Van Niel M. B., 1999, J. Med. Chem., 42, 2087, 10.1021/jm981133m · doi:10.1021/jm981133m
Sparr C., 2009, Angew. Chem., Int. Ed., 48, 3065, 10.1002/anie.200900405 · doi:10.1002/anie.200900405
Soloshonok V. A., 1996, Tetrahedron: Asymmetry, 7, 1547, 10.1016/0957-4166(96)00177-2 · doi:10.1016/0957-4166(96)00177-2
Wakeling A. E., 1991, Cancer Res., 51, 3867
Brazier E. J., 2010, Org. Process Res. Dev., 14, 544, 10.1021/op900315j · doi:10.1021/op900315j
Ballard P., 2006, Bioorg. Med. Chem. Lett., 16, 4908, 10.1016/j.bmcl.2006.06.054 · doi:10.1016/j.bmcl.2006.06.054
1996, Chem. Abstr., 126, 47235
2004, Chem. Abstr., 140, 287403
Chandregowda V., 2007, Org. Process Res. Dev., 11, 813, 10.1021/op700054p · doi:10.1021/op700054p
Breitler S., 2011, Org. Lett., 13, 3262, 10.1021/ol201210t · doi:10.1021/ol201210t
Rawling T., 2012, Tetrahedron, 68, 6065, 10.1016/j.tet.2012.05.002 · doi:10.1016/j.tet.2012.05.002
Wagstaff A. J., 2003, Drugs, 63, 217, 10.2165/00003495-200363020-00009 · doi:10.2165/00003495-200363020-00009
McGavin J. K., 2001, Drugs, 61, 2309, 10.2165/00003495-200161150-00015 · doi:10.2165/00003495-200161150-00015
Koukourakis G. V., 2008, Molecules, 13, 1897, 10.3390/molecules13081897 · DOI
Ishitsuka H., 1999, J. Pharm. Soc. Jpn., 119, 881, 10.1248/yakushi1947.119.12_881 · doi:10.1248/yakushi1947.119.12_881
Shimma N., 2000, Bioorg. Med. Chem., 8, 1697, 10.1016/S0968-0896(00)00087-0 · doi:10.1016/s0968-0896(00)00087-0
1981, Chem. Abstr., 95, 62602
Niedballa U., 1974, J. Org. Chem., 39, 3654, 10.1021/jo00939a008 · doi:10.1021/jo00939a008
Saneyoshi M., 1978, Chem. Pharm. Bull., 26, 2990, 10.1248/cpb.26.2990 · doi:10.1248/cpb.26.2990
Mendel D. B., 2003, Clin. Cancer Res., 9, 327
Manley J. M., 2003, J. Org. Chem., 68, 6447, 10.1021/jo034304q · doi:10.1021/jo034304q
Wang J.-Q., 2005, Bioorg. Med. Chem. Lett., 15, 4380, 10.1016/j.bmcl.2005.06.038 · doi:10.1016/j.bmcl.2005.06.038
Davies J., 2011, Lancet Oncol., 12, 826, 10.1016/S1470-2045(11)70228-5 · doi:10.1016/s1470-2045(11)70228-5
2004, Chem. Abstr., 140, 77161
Huang W.-S., 2007, Synthesis, 2121, 10.1055/s-2007-983754 · doi:10.1055/s-2007-983754
Ueda S., 2012, J. Am. Chem. Soc., 134, 700, 10.1021/ja2102373 · doi:10.1021/ja2102373
Basuli F., 2011, J. Labelled Compd. Radiopharm., 54, 633, 10.1002/jlcr.1898 · doi:10.1002/jlcr.1898
Wood E. R., 2004, Cancer Res., 64, 6652, 10.1158/0008-5472.CAN-04-1168 · DOI · Paper page
2002, Chem. Abstr., 137, 119644
Zhong W. Z., 2010, Curr. Drug Metab., 11, 296, 10.2174/138920010791514207 · doi:10.2174/138920010791514207
Pennell N. A., 2012, Am. J. Manag. Care, 18, SP84
2006, Chem. Abstr., 144, 274297
Ramachandran P. V., 2004, Tetrahedron Lett., 45, 2603, 10.1016/j.tetlet.2004.01.146 · doi:10.1016/j.tetlet.2004.01.146
Xin B., 2012, Bioorg. Med. Chem. Lett., 22, 4783, 10.1016/j.bmcl.2012.05.053 · doi:10.1016/j.bmcl.2012.05.053
Stellwagen J. C., 2011, Bioorg. Med. Chem. Lett., 21, 4436, 10.1016/j.bmcl.2011.06.021 · doi:10.1016/j.bmcl.2011.06.021
Buck J. R., 2012, Tetrahedron Lett., 53, 4161, 10.1016/j.tetlet.2012.05.137 · doi:10.1016/j.tetlet.2012.05.137
Baumann P., 2002, Eur. Neuropsychopharmacol., 12, 433, 10.1016/S0924-977X(02)00051-2 · DOI
Zhang P., 2010, J. Med. Chem., 53, 6112, 10.1021/jm1005034 · doi:10.1021/jm1005034
1990, Chem. Abstr., 113, 78150
2009, Chem. Abstr., 150, 144285
2005, Chem. Abstr., 143, 26491
2006, Chem. Abstr., 144, 292567
Elati C. R., 2007, Org. Process Res. Dev., 11, 289, 10.1021/op060175e · doi:10.1021/op060175e
2003, Chem. Abstr., 139, 73997
Solares L. F., 2004, Tetrahedron: Asymmetry, 15, 341, 10.1016/j.tetasy.2003.10.022 · doi:10.1016/j.tetasy.2003.10.022
2006, Chem. Abstr., 146, 80528
2007, Chem. Abstr., 147, 211613
Partridge B. M., 2011, Tetrahedron, 67, 10082, 10.1016/j.tet.2011.09.142 · doi:10.1016/j.tet.2011.09.142
Muñoz M., 2012, Expert Opin. Ther. Pat., 22, 735, 10.1517/13543776.2012.697153 · doi:10.1517/13543776.2012.697153
Lin P., 2007, Bioorg. Med. Chem. Lett., 17, 5191, 10.1016/j.bmcl.2007.06.085 · doi:10.1016/j.bmcl.2007.06.085
Jiang J., 2009, J. Med. Chem., 52, 3039, 10.1021/jm8016514 · doi:10.1021/jm8016514
Kolla N., 2007, Org. Process Res. Dev., 11, 455, 10.1021/op700030d · doi:10.1021/op700030d
Vankawala P. J., 2007, Synth. Commun., 37, 3439, 10.1080/00397910701487473 · doi:10.1080/00397910701487473
Pye P. J., 2002, Chem.—Eur. J., 8, 1372, 10.1002/1521-3765(20020315)8:6<1372::AID-CHEM1372>3.0.CO;2-6 · doi:10.1002/1521-3765(20020315)8:6<1372::aid-chem1372>3.0.co;2-6
Zhao M. M., 2002, J. Org. Chem., 67, 6743, 10.1021/jo0203793 · doi:10.1021/jo0203793
Cowden C. J., 2000, Tetrahedron Lett., 41, 8661, 10.1016/S0040-4039(00)01548-3 · doi:10.1016/s0040-4039(00)01548-3
Payack J. F., 2004, Org. Process Res. Dev., 8, 256, 10.1021/op034180j · doi:10.1021/op034180j
2012, Chem. Abstr., 157, 663055
2009, Chem. Abstr., 151, 343563
Elati C. R., 2007, Tetrahedron Lett., 48, 8001, 10.1016/j.tetlet.2007.09.051 · doi:10.1016/j.tetlet.2007.09.051
Gangula S., 2010, Synth. Commun., 40, 2254, 10.1080/00397910903221084 · doi:10.1080/00397910903221084
Brands K. M. J., 2006, Org. Process Res. Dev., 10, 109, 10.1021/op0501895 · doi:10.1021/op0501895
Nelson T. D., 2004, Tetrahedron Lett., 45, 8917, 10.1016/j.tetlet.2004.09.185 · doi:10.1016/j.tetlet.2004.09.185
Strupczewski J. T., 1995, J. Med. Chem., 38, 1119, 10.1021/jm00007a009 · doi:10.1021/jm00007a009
Rado J., 2010, Expert Opin. Pharmacother., 11, 2087, 10.1517/14656566.2010.502889 · doi:10.1517/14656566.2010.502889
1993, Chem. Abstr., 118, 240939
2008, Chem. Abstr., 148, 308371
2011, Chem. Abstr., 155, 123430
2011, Chem. Abstr., 154, 158482
2011, Chem. Abstr., 155, 123425
2012, Chem. Abstr., 157, 548664
Janardhana R. V., 2011, Pharm. Lett., 3, 240
2010, Chem. Abstr., 152, 144708
Strupczewski J. T., 1985, J. Med. Chem., 28, 761, 10.1021/jm00383a012 · doi:10.1021/jm00383a012
1991, Chem. Abstr., 114, 185553
1995, Chem. Abstr., 123, 169657
1995, Chem. Abstr., 123, 314016
1998, Chem. Abstr., 129, 122674
2012, Chem. Abstr., 157, 708577
2010, Chem. Abstr., 152, 405725
Patel D. S., 2011, Res. J. Pharm. Biol. Chem. Sci, 2, 855
Hegde S., 2008, Annu. Rep. Med. Chem., 43, 455
Wang J., 2006, Prog. Nat. Sci., 16, 925, 10.1080/10020070612330017 · DOI
1987, Chem. Abstr., 106, 156480
1999, Chem. Abstr., 130, 57245
2010, Chem. Abstr., 153, 382966
1998, Chem. Abstr., 128, 140707
Arava V. R., 2011, Pharm. Chem., 3, 381
2012, Chem. Abstr., 156, 337316
2012, Chem. Abstr., 156, 390181
Dorange I., 2011, Annu. Rep. Med. Chem., 46, 53
1993, Chem. Abstr., 119, 225705
2003, Chem. Abstr., 138, 137040
2012, Chem. Abstr., 157, 242074
1998, Chem. Abstr., 129, 104236
Swahn C.-G., 1996, J. Labelled Compd. Radiopharm., 38, 675, 10.1002/(SICI)1099-1344(199607)38:7<675::AID-JLCR880>3.0.CO;2-L · doi:10.1002/(sici)1099-1344(199607)38:7<675::aid-jlcr880>3.0.co;2-l
2011, Chem. Abstr., 155, 94042
Wu G., 1999, J. Org. Chem., 64, 3714, 10.1021/jo990428k · doi:10.1021/jo990428k
Fu X., 2003, Tetrahedron Lett., 44, 801, 10.1016/S0040-4039(02)02700-4 · doi:10.1016/s0040-4039(02)02700-4
Bertrand B., 2007, Tetrahedron Lett., 48, 2123, 10.1016/j.tetlet.2007.01.118 · doi:10.1016/j.tetlet.2007.01.118
Kysliková E., 2010, J. Mol. Catal. B: Enzym., 67, 266, 10.1016/j.molcatb.2010.09.006 · doi:10.1016/j.molcatb.2010.09.006
Sova M., 2010, Synthesis, 3433
Michalak M., 2011, J. Org. Chem., 76, 6931, 10.1021/jo2010846 · doi:10.1021/jo2010846
Wang X., 2012, Angew. Chem., Int. Ed., 51, 9276, 10.1002/anie.201204925 · doi:10.1002/anie.201204925
aPfefferkorn, J. A.InThe art of drug synthesis;Johnson, D. S.; Li, J. J., Eds.John Wiley & Sons:Hoboken, NJ, 2007; pp169–182.
Quirk J., 2003, Nat. Rev. Drug. Discovery, 2, 769, 10.1038/nrd1205 · doi:10.1038/nrd1205
Konoike T., 1994, J. Org. Chem., 59, 7849, 10.1021/jo00104a049 · doi:10.1021/jo00104a049
Korostylev A., 2008, Eur. J. Org. Chem., 840, 10.1002/ejoc.200701059 · doi:10.1002/ejoc.200701059
Andrushko N., 2008, Eur. J. Org. Chem., 847, 10.1002/ejoc.200700813 · doi:10.1002/ejoc.200700813
Časar Z., 2008, Synlett, 2036, 10.1055/s-2008-1077957 · doi:10.1055/s-2008-1077957
Časar Z., 2009, Synlett, 1144, 10.1055/s-0028-1088152 · doi:10.1055/s-0028-1088152
Hilas O., 2009, Pharm. Ther., 34, 188
Siebert C. D., 2008, Chirality, 20, 103, 10.1002/chir.20509 · doi:10.1002/chir.20509
Bai Y., 2006, J. Chem. Res., 807, 10.3184/030823406780199802 · doi:10.3184/030823406780199802
Johannes C. W., 1998, J. Am. Chem. Soc., 120, 8340, 10.1021/ja981378o · doi:10.1021/ja981378o
Visser M. S., 1996, J. Am. Chem. Soc., 118, 3779, 10.1021/ja960263m · doi:10.1021/ja960263m
Harrity J. P. A., 1997, J. Am. Chem. Soc., 119, 1488, 10.1021/ja9636597 · doi:10.1021/ja9636597
Encinas M. V., 1980, J. Am. Chem. Soc., 102, 1357, 10.1021/ja00524a021 · doi:10.1021/ja00524a021
Trost B. M., 1988, Tetrahedron Lett., 29, 2931, 10.1016/0040-4039(88)85050-0 · doi:10.1016/0040-4039(88)85050-0
Hoveyda A. H., 1993, Chem. Rev., 93, 1307, 10.1021/cr00020a002 · doi:10.1021/cr00020a002
Chandrasekhar S., 2000, Tetrahedron, 56, 6339, 10.1016/S0040-4020(00)00572-X · doi:10.1016/s0040-4020(00)00572-x
Wang N.-X., 2007, Synthesis, 1154, 10.1055/s-2007-965993 · doi:10.1055/s-2007-965993
Carreño M. C., 2008, Eur. J. Org. Chem., 2035, 10.1002/ejoc.200800201 · doi:10.1002/ejoc.200800201
Nakagawa S., 1995, Jpn. J. Pharm., 67, 1, 10.1254/jjp.67.1 · doi:10.1254/jjp.67.1
Müller M., 2005, Angew. Chem., Int. Ed., 44, 362, 10.1002/anie.200460852 · doi:10.1002/anie.200460852
Karanewsky D. S., 1991, J. Org. Chem., 56, 3744, 10.1021/jo00011a064 · doi:10.1021/jo00011a064
Theisen P. D., 1988, J. Org. Chem., 53, 2374, 10.1021/jo00245a051 · doi:10.1021/jo00245a051
Heathcock C. H., 1987, J. Med. Chem., 30, 1858, 10.1021/jm00393a030 · doi:10.1021/jm00393a030
Rosen T., 1985, J. Am. Chem. Soc., 107, 3731, 10.1021/ja00298a062 · doi:10.1021/ja00298a062
Rosen T., 1984, J. Org. Chem., 49, 3657, 10.1021/jo00193a044 · doi:10.1021/jo00193a044
Fernandes R. A., 2002, Eur. J. Org. Chem., 2921, 10.1002/1099-0690(200209)2002:17<2921::AID-EJOC2921>3.0.CO;2-N · doi:10.1002/1099-0690(200209)2002:17<2921::aid-ejoc2921>3.0.co;2-n
Ghosh A. K., 2002, J. Org. Chem., 67, 8783, 10.1021/jo020402k · doi:10.1021/jo020402k
Rosen T., 1984, J. Org. Chem., 49, 3994, 10.1021/jo00195a023 · doi:10.1021/jo00195a023
Kumar P., 2010, Tetrahedron Lett., 51, 5838, 10.1016/j.tetlet.2010.08.093 · doi:10.1016/j.tetlet.2010.08.093
Reddy M. V. R., 2001, J. Organomet. Chem., 624, 239, 10.1016/S0022-328X(01)00665-9 · doi:10.1016/s0022-328x(01)00665-9
Takahashi K., 1993, Tetrahedron Lett., 34, 8263, 10.1016/S0040-4039(00)61406-5 · doi:10.1016/s0040-4039(00)61406-5
Lopp M., 1991, Tetrahedron: Asymmetry, 2, 943, 10.1016/S0957-4166(00)86131-5 · doi:10.1016/s0957-4166(00)86131-5
Minami T., 1992, Tetrahedron Lett., 33, 7525, 10.1016/S0040-4039(00)60814-6 · doi:10.1016/s0040-4039(00)60814-6
Reddy B., 1991, J. Org. Chem., 56, 5752, 10.1021/jo00020a008 · doi:10.1021/jo00020a008
Takano S., 1993, Tetrahedron: Asymmetry, 4, 201, 10.1016/S0957-4166(00)82337-X · doi:10.1016/s0957-4166(00)82337-x
Miyachi N., 1993, Tetrahedron Lett., 34, 8267, 10.1016/S0040-4039(00)61407-7 · doi:10.1016/s0040-4039(00)61407-7
Suzuki M., 2001, Bioorg. Med. Chem., 9, 2727, 10.1016/S0968-0896(01)00198-5 · DOI
Acemoglu M., 2007, Helv. Chim. Acta, 90, 1069, 10.1002/hlca.200790106 · doi:10.1002/hlca.200790106
Fabris J., 2012, Synthesis, 1700
Serebruany V., 2009, Thromb. Haemostasis, 101, 14, 10.1160/TH08-07-0452 · doi:10.1160/th08-07-0452
Huber K., 2009, Nat. Rev. Drug Discovery, 8, 449, 10.1038/nrd2899 · doi:10.1038/nrd2899
Hasegawa M., 2005, Thromb. Haemostasis, 94, 593, 10.1160/TH05-03-0208 · doi:10.1160/th05-03-0208
Dobesh P. P., 2009, Pharmacotherapy, 29, 1393, 10.1592/phco.29.12.1393 · doi:10.1592/phco.29.12.1393
2009, Chem. Abstr., 151, 266755
Aalla S., 2012, Org. Process Res. Dev., 16, 240, 10.1021/op200325u · doi:10.1021/op200325u
Pan X., 2012, Tetrahedron Lett., 53, 5364, 10.1016/j.tetlet.2012.07.071 · doi:10.1016/j.tetlet.2012.07.071
Zhang H., 2012, Bioorg. Med. Chem. Lett., 22, 3598, 10.1016/j.bmcl.2012.04.050 · doi:10.1016/j.bmcl.2012.04.050
Groll A. H., 1998, Adv. Pharmacol. (San Diego, CA, U.S.), 44, 343
Tasaka A., 1993, Chem. Pharm. Bull., 41, 1035, 10.1248/cpb.41.1035 · doi:10.1248/cpb.41.1035
Richardson K., 1988, Ann. N.Y. Acad. Sci., 544, 6
Tasaka A., 1995, Chem. Pharm. Bull., 43, 441, 10.1248/cpb.43.441 · doi:10.1248/cpb.43.441
Butters M., 2001, Org. Process Res. Dev., 5, 28, 10.1021/op0000879 · doi:10.1021/op0000879
1997, Chem. Abstr., 127, 262316
1995, Chem. Abstr., 123, 339705
Butters M., 1992, J. Heterocycl. Chem., 1369, 10.1002/jhet.5570290554 · doi:10.1002/jhet.5570290554
Frampton J. E., 2005, Drugs, 65, 1427, 10.2165/00003495-200565100-00008 · doi:10.2165/00003495-200565100-00008
Molina J. M., 2005, Drugs Today, 41, 241, 10.1358/dot.2005.41.4.900219 · doi:10.1358/dot.2005.41.4.900219
Cahn P., 2004, Expert Opin. Invest. Drugs, 13, 55, 10.1517/13543784.13.1.55 · doi:10.1517/13543784.13.1.55
Bang L. M., 2003, Drugs, 63, 2413, 10.2165/00003495-200363220-00003 · doi:10.2165/00003495-200363220-00003
Gentile I., 2006, Curr. Med. Chem., 13, 2839, 10.2174/092986706778521995 · doi:10.2174/092986706778521995
Nelson M., 2004, Int. J. Clin. Pract., 58, 504, 10.1111/j.1368-5031.2004.00100.x · doi:10.1111/j.1368-5031.2004.00100.x
1992, Chem. Abstr., 118, 22551
2000, Chem. Abstr., 132, 166456
Hoong L. K., 1992, J. Org. Chem., 57, 5563, 10.1021/jo00047a004 · doi:10.1021/jo00047a004
Osborne A. P., 2006, Org. Process Res. Dev., 10, 670, 10.1021/op050258f · doi:10.1021/op050258f
Gaede B. J., 2005, Org. Process Res. Dev., 9, 23, 10.1021/op040210m · doi:10.1021/op040210m
Agarwal H. K., 2012, J. Med. Chem., 55, 2672, 10.1021/jm201551m · doi:10.1021/jm201551m
Agarwal H. K., 2013, Mol. Pharmaceutics, 10, 467, 10.1021/mp300361a · doi:10.1021/mp300361a
Rusconi S., 2009, Expert Rev. Clin. Pharmacol., 2, 147, 10.1586/17512433.2.2.147 · doi:10.1586/17512433.2.2.147
Orman J. S., 2008, Drugs, 68, 1435, 10.2165/00003495-200868100-00006 · doi:10.2165/00003495-200868100-00006
Temesgen Z., 2005, Drugs Today, 41, 71, 10.1358/dot.2005.41.11.937960 · doi:10.1358/dot.2005.41.11.937960
Wroblewski A., 1998, Drugs Future, 23, 146, 10.1358/dof.1998.023.02.445832 · doi:10.1358/dof.1998.023.02.445832
Thaisrivongs S., 1996, J. Med. Chem., 39, 4349, 10.1021/jm960541s · doi:10.1021/jm960541s
Turner S. R., 1998, J. Med. Chem., 41, 3467, 10.1021/jm9802158 · doi:10.1021/jm9802158
Judge T. M., 1997, J. Am. Chem. Soc., 119, 3627, 10.1021/ja963434w · doi:10.1021/ja963434w
Soloshonok V. A., 2002, Helv. Chim. Acta, 85, 3616, 10.1002/1522-2675(200211)85:11<3616::AID-HLCA3616>3.0.CO;2-O · doi:10.1002/1522-2675(200211)85:11<3616::aid-hlca3616>3.0.co;2-o

200 of 301 shown

Photoredox Catalysis in Organic Chemistry
Shaw, M. H., Twilton, J., & MacMillan, D. W. C. (2016) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.6b01449 · Cited by 3,186
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
Meanwell, N. A. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01788 · Cited by 2,655
3d Transition Metals for C–H Activation
Gandeepan, P., Müller, T., Zell, D., Cera, G., Warratz, S., & Ackermann, L. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00507 · Cited by 2,332
Contribution of Organofluorine Compounds to Pharmaceuticals
Inoue, M., Sumii, Y., & Shibata, N. (2020) · ACS Omega · doi:10.1021/acsomega.0c00830 · Cited by 1,944
Current Contributions of Organofluorine Compounds to the Agrochemical Industry
Ogawa, Y., Tokunaga, E., Kobayashi, O., Hirai, K., & Shibata, N. (2020) · iScience · doi:10.1016/j.isci.2020.101467 · Cited by 1,253

See all 4,847

Authors: Wang, J., Sánchez-Roselló, M., Aceña, J. L., del Pozo, C., Sorochinsky, A. E., Fustero, S., Soloshonok, V. A., & Liu, H.
Venue: Chemical Reviews
Publisher: American Chemical Society (ACS)
Published: 2013-12-03
Volume: 114
Issue: 4
Pages: 2432-2506
ISSN: 0009-2665 (ISSN-L)
1520-6890
DOI: 10.1021/cr4002879
OpenAlex: W2333129245
Cited by: 4,847
References: 254
FWCI: 75.99
Type: journal article
Language: en
Open access: closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Metadata

Record

About these checks

Data sources